ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative conditions. Through this collaboration, GSK will leverage Grabody-B ...

Neuroscience isn't currently one of the top strategic R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting. The UK-headquartered pharma group is ...

(RTTNews) - ABL Bio Inc. announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier or BBB shuttle ...

GSK and ABL Bio have entered into an agreement worth over £2bn to develop new drugs for neurodegenerative diseases. The global licensing deal will allow GSK to use ABL Bio’s blood-brain barrier (BBB) ...

As part of the agreement, ABL Bio will transfer Grabody-B-related technology and know-how to GSK, while GSK will assume responsibility for preclinical and clinical development, manufacturing ...

GSK signed a deal worth up to $2.5 billion for ABL Bio's neuroscience technology. And more. 1. Congressional commission urges $15B, more action to maintain US biotech advantage over China The U.S ...

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in itching that began after two weeks and persisted through the 24-week primary ...

April 15 (Reuters) - British pharmaceutical giant GSK (GSK.L), opens new tab has not met required ethical and regulatory standards in the marketing and prescription information for its Omjjara ...